Applying Shared Decision Making in Cancer Treatment and Management to Optimize Multidisciplinary Care
A Docuseries on Cutaneous Malignancies: Cutaneous Squamous Cell Carcinoma (cSCC)
PROGRAM CHAIR & FACULTY
Emily S. Ruiz, MD, MPH
Associate Professor of Dermatology
Harvard Medical School
Director, High-Risk Skin Cancer Clinic
Dana-Farber Cancer Institute
Program Director, Micrographic Surgery and Dermatology Oncology Fellowship
Brigham and Women’s Hospital
Boston, MA
FEATURING
Robert Lambert
Tewksbury, MA
PROGRAM OVERVIEW
This enduring activity uses a unique documentary approach to share the patient experience of diagnosis and treatment of cutaneous squamous cell carcinoma (cSCC). It highlights their experiences with surgery, radiation, chemotherapy, and immunotherapy with commentary from our faculty expert. The goal is to help learners identify potential immune targets and systemic treatment strategies; optimize multidisciplinary management; and incorporate shared decision making in arriving at individualized care for their patients with cSCC.
TARGET AUDIENCE
This program will reach the medical oncology team, including dermatologists, oncologists, and other healthcare professionals working collaboratively to provide the best possible care for patients with cutaneous malignancies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement best practices for assessment of targetable mutations and eligibility for immuno-therapeutic treatment of cutaneous malignancies
- Integrate best practices for patient education and communication, including strategies for discussing treatment options, concerns and monitoring for/managing adverse events
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosure |
| Emily S. Ruiz, MD | Dr. Ruiz reports that she is a consultant for Checkpoint Therapeutics, Regeneron Pharmaceuticals, and Feldman Pharmaceuticals. She also serves as a principal investigator/co-investigator for Regeneron Pharmaceuticals, and a co-investigator for Merck and Castle Biosciences. |
| Robert Lambert | Robert reports that he has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, PhD, discloses that he receives UpToDate author royalties from Wolters Kluwer.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 31, 2024
EXPIRATION DATE: January 31, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
A Docuseries on Cutaneous Malignancies: Cutaneous Squamous Cell Carcinoma (cSCC)
PROGRAM CHAIR & FACULTY
Emily S. Ruiz, MD, MPH
Associate Professor of Dermatology
Harvard Medical School
Director, High-Risk Skin Cancer Clinic
Dana-Farber Cancer Institute
Program Director, Micrographic Surgery and Dermatology Oncology Fellowship
Brigham and Women’s Hospital
Boston, MA
FEATURING
Nancy Garrity
Norwood, MA
PROGRAM OVERVIEW
This enduring activity uses a unique documentary approach to share the patient experience of diagnosis and treatment of cutaneous squamous cell carcinoma (cSCC). It highlights their experiences with surgery, radiation, chemotherapy, and immunotherapy with commentary from our faculty expert. The goal is to help learners identify potential immune targets and systemic treatment strategies; optimize multidisciplinary management; and incorporate shared decision making in arriving at individualized care for their patients with cSCC.
TARGET AUDIENCE
This program will reach the medical oncology team, including dermatologists, oncologists, and other healthcare professionals working collaboratively to provide the best possible care for patients with cutaneous malignancies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement best practices for assessment of targetable mutations and eligibility for immuno-therapeutic treatment of cutaneous malignancies
- Identify potential unique adverse events associated with novel therapeutics and implement patient-centric education, monitoring and reporting protocols
- Integrate best practices for patient education and communication, including strategies for discussing treatment options, concerns and monitoring for/managing adverse events
- Establish best practices for peer-to-peer expert communication for optimal multidisciplinary care of patients with cutaneous malignancies.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosure |
| Emily S. Ruiz, MD | Dr. Ruiz reports that she is a consultant for Checkpoint Therapeutics, Regeneron Pharmaceuticals, and Feldman Pharmaceuticals. She also serves as a principal investigator/co-investigator for Regeneron Pharmaceuticals, and a co-investigator for Merck and Castle Biosciences. |
| Nancy Garrity | Nancy reports that she has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, PhD, discloses that he receives UpToDate author royalties from Wolters Kluwer.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 31, 2024
EXPIRATION DATE: January 31, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
A Docuseries on Cutaneous Malignancies: Melanoma
PROGRAM CHAIR & FACULTY
Yana G. Najjar, MD
Assistant Professor of Medicine
Director, Clinical and Translational Research Center
UPMC Hillman Cancer Center
Pittsburgh, PA
FEATURING
Robert Meyers
Pittsburgh, PA
PROGRAM OVERVIEW
This enduring activity uses a unique documentary approach to share the patient experience of diagnosis and treatment of metastatic melanoma. It highlights their experiences with surgery, radiation, chemotherapy, and immunotherapy with commentary from our faculty expert. The goal is to help learners identify potential immune targets and systemic treatment strategies; optimize multidisciplinary management; and incorporate shared decision making in arriving at individualized care for their patients with metastatic melanoma.
TARGET AUDIENCE
This program will reach the medical oncology team, including dermatologists, oncologists, and other healthcare professionals working collaboratively to provide the best possible care for patients with cutaneous malignancies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement best practices for assessment of targetable mutations and eligibility for immuno-therapeutic treatment of cutaneous malignancies
- Identify potential unique adverse events associated with novel therapeutics and implement patient-centric education, monitoring and reporting protocols
- Integrate best practices for patient education and communication, including strategies for discussing treatment options, concerns and monitoring for/managing adverse events
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosure |
| Yana G. Najjar, MD | Dr. Najjar reports that she is a consultant for Merck, Bristol Myers Squibb, Pfizer, Novartis, Immunocore, and InterVenn Biosciences. She also participates in speaker’s bureaus for Pfizer and Immunocore. Dr. Najjar receives fees for Non-CME/CE Services from Pfizer and Immunocore. She also receives contracted research funding from Merck, Pfizer, Bristol Myers Squibb, and Replimune. She also travels for Istari Oncology. |
| Robert Meyers | Robert reports that he has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, PhD, discloses that he receives UpToDate author royalties from Wolters Kluwer.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 31, 2024
EXPIRATION DATE: January 31, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
